Johnson & Johnson, through its Janssen subsidiary, will collaborate with a US government agency, the Biomedical Advanced Research and Development Authority (BARDA), to expedite development of a coronavirus vaccine. BARDA will provide funding to bring a candidate into Phase I clinical studies, with further support possible. Previously, Janssen developed a vaccine for Ebola, a similar infection to COVID-19, as well as vaccine candidates for Zika, RSV and HIV. J&J is also working with global partners to screen its library of antiviral molecules to discover other potential candidates for COVID-19. More details....
Stock Symbol: (NYSE: JNJ)
Share this with colleagues:
Original Article: J&J Collaborates with BARDA, a US Agency, to Develop COVID-19 Vaccine